Baird Financial Group
CRBP icon

Baird Financial Group’s Corbus Pharmaceuticals CRBP Stock Holding History

Baird Financial Group’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-367
Closed -$11K – 1885
2021
Q3 		$11K Buy
+367
New +$14.5K ﹤0.01% 1849

Other funds holding CRBP

EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Baird Financial Group's CRBP Position: Q4 2021 in Review

Baird Financial Group sold out of Corbus Pharmaceuticals (CRBP) in Q4 2021, closing a stake of 367 shares — an estimated $11K sold.

Baird Financial Group first reported a position in CRBP in Q3 2021 and held it in 1 quarter. The position peaked at $11K in Q3 2021. 82 funds tracked by Wall St. Rank hold CRBP as of Q4 2021.

  • Baird Financial Group reported no remaining Corbus Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Baird Financial Group sold 367 Corbus Pharmaceuticals shares in Q4 2021, an estimated $11K.
  • Baird Financial Group first reported a position in Corbus Pharmaceuticals in Q3 2021 and held it in 1 quarter.
  • Baird Financial Group's Corbus Pharmaceuticals position peaked at $11K in Q3 2021.
  • 82 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q4 2021.

Based on Baird Financial Group's 13F filing for Q4 2021, filed 9 Feb 2022.